Phase I Study of Weekly Vinorelbine in Combination with Weekly Paclitaxel in Adult Patients with Advanced Refractory Cancer
Authors:
- 1 January 2000
- journal article
- research article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 18 (5) , 422-428
Abstract
Vinorelbine and paclitaxel are highly active antineoplastic agents. Preclinical data indicate a potential for antitumor synergy for a number of common tumor types when they are combined. We investigated a novel weekly schedule of both agents. Eighteen patients with advanced cancer were entered onto this phase I trial. Vinorelbine and paclitaxel were given weekly in combination for 6 consecutive weeks, followed by a 2-week break. Sequential cohorts of patients were treated at two dose levels: Vinorelbine 22.5 mg/m2 followed by paclitaxel 40 mg/m2 and Vinorelbine 22.5 mg/m2 followed by paclitaxel 60 mg/m2. Ten patients completed at least one 8-week course of therapy. Neutropenic myelosuppression was dose limiting at level II. Neurotoxicity was not dose limiting. Objective responses were seen in patients with esophageal, lung, and breast cancer and suggest that this is an active regimen worthy of further investigation in selected diseases. Phase II trials of this regimen are in progress.Keywords
This publication has 17 references indexed in Scilit:
- The effect of combining antitubulin agents on differentiated and undifferentiated human colon cancer cellsAnti-Cancer Drugs, 1998
- Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancerBreast Cancer Research and Treatment, 1998
- Phase I study of vinorelbine and paclitaxel in small-cell lung cancerCancer Chemotherapy and Pharmacology, 1997
- In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell linesEuropean Journal of Cancer, 1997
- Re: Severe Neurotoxicity in Vinorelbine-Paclitaxel CombinationsJNCI: Journal of the National Cancer Institute, 1997
- Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: A phase II studyAnnals of Oncology, 1996
- Severe Neurotoxicity From Vinorelbine-Paclitaxel CombinationsJNCI: Journal of the National Cancer Institute, 1996
- Vinorelbine Tartrate and Paclitaxel Combinations: Enhanced Activity Against In Vivo P388 Murine Leukemia CellsJNCI: Journal of the National Cancer Institute, 1995
- A Phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancerLung Cancer, 1994
- Promotion of microtubule assembly in vitro by taxolNature, 1979